Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer

Roche announced today that the European Commission has granted a conditional marketing authorisation for Alecensa ® (alectinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news